Amundi Purchases 42,907 Shares of Certara, Inc. (NASDAQ:CERT)

Amundi increased its position in Certara, Inc. (NASDAQ:CERT) by 222.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 62,167 shares of the company’s stock after buying an additional 42,907 shares during the period. Amundi’s holdings in Certara were worth $685,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Venturi Wealth Management LLC boosted its holdings in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after buying an additional 2,509 shares during the period. Blue Trust Inc. increased its holdings in Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after acquiring an additional 822 shares during the last quarter. KBC Group NV increased its holdings in Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares during the last quarter. GAMMA Investing LLC increased its holdings in Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after acquiring an additional 6,868 shares during the last quarter. Finally, Moloney Securities Asset Management LLC bought a new stake in Certara in the 4th quarter valued at $128,000. Institutional investors own 73.96% of the company’s stock.

Certara Price Performance

CERT stock opened at $10.69 on Thursday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.18. The firm has a market capitalization of $1.72 billion, a P/E ratio of -53.45, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. The company has a fifty day simple moving average of $12.55 and a two-hundred day simple moving average of $11.51.

Wall Street Analyst Weigh In

CERT has been the topic of a number of research reports. William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. TD Cowen initiated coverage on shares of Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target on the stock. Barclays lifted their price target on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Finally, Stephens reiterated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Certara has an average rating of “Moderate Buy” and an average target price of $15.83.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.